SG11201908919XA - Combination therapies targeting pd-1, tim-3, and lag-3 - Google Patents

Combination therapies targeting pd-1, tim-3, and lag-3

Info

Publication number
SG11201908919XA
SG11201908919XA SG11201908919XA SG11201908919XA SG 11201908919X A SG11201908919X A SG 11201908919XA SG 11201908919X A SG11201908919X A SG 11201908919XA SG 11201908919X A SG11201908919X A SG 11201908919XA
Authority
SG
Singapore
Prior art keywords
international
rule
tim
lag
applicant
Prior art date
Application number
Other languages
English (en)
Inventor
Trine Lindsted
Michael Monrad Grandal
Eva Maria Carlsen Melander
Camilla Fröhlich
Mikkel Wandahl Pedersen
Michael Kragh
Johan Lantto
Monika Gad
Ivan David Horak
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of SG11201908919XA publication Critical patent/SG11201908919XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Memory System Of A Hierarchy Structure (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201908919X 2017-04-05 2018-04-05 Combination therapies targeting pd-1, tim-3, and lag-3 SG11201908919XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481973P 2017-04-05 2017-04-05
PCT/EP2018/058752 WO2018185232A1 (en) 2017-04-05 2018-04-05 Combination therapies targeting pd-1, tim-3, and lag-3

Publications (1)

Publication Number Publication Date
SG11201908919XA true SG11201908919XA (en) 2019-10-30

Family

ID=62027945

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201908919X SG11201908919XA (en) 2017-04-05 2018-04-05 Combination therapies targeting pd-1, tim-3, and lag-3
SG10201912941PA SG10201912941PA (en) 2017-04-05 2018-04-05 Combination therapies targeting pd-1, tim-3, and lag-3

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912941PA SG10201912941PA (en) 2017-04-05 2018-04-05 Combination therapies targeting pd-1, tim-3, and lag-3

Country Status (19)

Country Link
US (2) US11939380B2 (ko)
EP (3) EP3606957A1 (ko)
JP (3) JP2020513009A (ko)
KR (2) KR20220083863A (ko)
CN (2) CN114984209A (ko)
AU (2) AU2018247916A1 (ko)
BR (1) BR112019020662A2 (ko)
CA (2) CA3058960C (ko)
CL (2) CL2019002850A1 (ko)
CO (1) CO2019012080A2 (ko)
EA (1) EA201992350A1 (ko)
IL (1) IL269644A (ko)
MA (1) MA49042A (ko)
MX (2) MX2019011961A (ko)
PE (1) PE20191741A1 (ko)
PH (1) PH12019502191A1 (ko)
SG (2) SG11201908919XA (ko)
TW (2) TWI801376B (ko)
WO (1) WO2018185232A1 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3443009T3 (da) 2016-04-12 2021-12-13 Symphogen As Anti-tim-3-antistoffer og sammensætninger
CN117683135A (zh) 2016-07-14 2024-03-12 百时美施贵宝公司 针对tim3的抗体及其用途
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
AU2017342071A1 (en) 2016-10-13 2019-04-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Anti-LAG-3 antibodies and compositions
AU2018247765B2 (en) 2017-04-03 2023-11-23 F. Hoffmann-La Roche Ag Immunoconjugates of an Anti-PD-1 antibody with a mutant IL-2 or with IL-15
IL268527B2 (en) 2017-04-05 2024-03-01 Hoffmann La Roche Bispecific antibodies bind to PD1 and LAG3 specifically
KR20220083863A (ko) 2017-04-05 2022-06-20 심포젠 에이/에스 Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
CN111253485A (zh) * 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 抗人tim-3单克隆抗体及其应用
EP3969040A1 (en) * 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
CN113214396B (zh) * 2020-07-31 2022-04-19 北京市神经外科研究所 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途
CN112812179B (zh) * 2021-01-19 2022-07-22 北京大学 高亲和力高特异性抗cmtm6单克隆抗体及其用途
WO2023240082A2 (en) * 2022-06-07 2023-12-14 Incyte Corporation Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
WO2024041651A1 (en) * 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies
WO2024041652A1 (en) * 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment
WO2024051670A1 (zh) * 2022-09-06 2024-03-14 正大天晴药业集团股份有限公司 结合tim-3的抗体与结合pd-1的抗体的药物组合

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
JP3700859B2 (ja) 1994-05-06 2005-09-28 アンスティテュ ギュスタブ ルシ Ｌａｇ−３タンパク質の可溶性ポリペプチドフラクション；製造方法、治療用製剤、抗イディオタイプ抗体
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
PT1583830E (pt) 2003-01-07 2006-11-30 Symphogen As Método para produzir proteínas policlonais recombinantes
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2427646T5 (es) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101105610B1 (ko) 2006-08-17 2012-01-18 에프. 호프만-라 로슈 아게 Ｃｃｒ５ 에 대한 항체 및 항푸소제닉 펩타이드의 컨쥬게이트
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2008145133A2 (en) 2007-05-25 2008-12-04 Symphogen A/S Method for manufacturing a recombinant polyclonal protein
RS53072B (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1
US20110059106A1 (en) 2008-01-29 2011-03-10 Brigham And Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
RU2010147652A (ru) 2008-04-23 2012-05-27 Симфоген А/С (Dk) Способы производства поликлонального белка
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
US9181342B2 (en) 2008-09-12 2015-11-10 Isis Innovation Limited PD-1 specific antibodies and uses thereof
MX2011003480A (es) 2008-10-06 2011-04-21 Symphogen As Metodo para identificar y seleccionar candidatos de farmaco para productos de farmacos de combinacion.
WO2010084999A1 (en) 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP3363499A1 (en) 2010-06-11 2018-08-22 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody
US9163087B2 (en) * 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US9217039B2 (en) 2010-11-01 2015-12-22 Symphogen A/S Anti-HER3 antibodies and compositions
LT2691112T (lt) 2011-03-31 2018-07-25 Merck Sharp & Dohme Corp. Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
KR101933990B1 (ko) 2012-05-02 2018-12-31 심포젠 에이/에스 인간화 ｐａｎ­ｈｅｒ 항체 조성물
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP2016508504A (ja) 2013-02-01 2016-03-22 サンタ マリア バイオセラピューティクス インコーポレイテッド 対象に対する抗アクチビン−ａ化合物の投与
EP2970464B1 (en) 2013-03-15 2020-05-06 GlaxoSmithKline Intellectual Property Development Limited Anti-lag-3 binding proteins
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
RS64268B1 (sr) * 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CN105026428B (zh) 2013-12-12 2018-01-16 上海恒瑞医药有限公司 PD‑l抗体、其抗原结合片段及其医药用途
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN103936853B (zh) 2014-01-26 2016-08-17 中国人民解放军军事医学科学院基础医学研究所 一种检测tim-3试剂盒及其使用方法
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR20200029627A (ko) 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
CN106103484B (zh) 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
IL248511B (en) * 2014-05-13 2022-07-01 Bavarian Nordic As Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
US10428146B2 (en) 2014-07-22 2019-10-01 Cb Therapeutics, Inc. Anti PD-1 antibodies
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TW201639888A (zh) 2015-03-06 2016-11-16 索倫多醫療公司 結合ｔｉｍ３之抗體治療劑
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US11014983B2 (en) 2015-08-20 2021-05-25 Sutro Biopharma, Inc. Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies
SI3356411T1 (sl) 2015-10-02 2021-09-30 F. Hoffmann-La Roche Ag Bispecifična protitelesa, specifična za PD1 in TIM3
US20210284734A1 (en) 2015-10-02 2021-09-16 Symphogen A/S Anti-pd-1 antibodies and compositions
JP6875385B2 (ja) 2015-10-02 2021-05-26 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｐｄ−１抗体および組成物
DK3443009T3 (da) 2016-04-12 2021-12-13 Symphogen As Anti-tim-3-antistoffer og sammensætninger
EA201892616A1 (ru) 2016-05-18 2019-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Антитела к pd1 и lag3 для лечения злокачественного новообразования
CN117683135A (zh) 2016-07-14 2024-03-12 百时美施贵宝公司 针对tim3的抗体及其用途
JOP20190013A1 (ar) 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
AU2017342071A1 (en) 2016-10-13 2019-04-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Anti-LAG-3 antibodies and compositions
US11359018B2 (en) 2016-11-18 2022-06-14 Symphogen A/S Anti-PD-1 antibodies and compositions
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
KR20220083863A (ko) 2017-04-05 2022-06-20 심포젠 에이/에스 Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3

Also Published As

Publication number Publication date
SG10201912941PA (en) 2020-02-27
EP3606957A1 (en) 2020-02-12
PE20191741A1 (es) 2019-12-12
PH12019502191A1 (en) 2020-06-15
CN110621698A (zh) 2019-12-27
EP4230654A1 (en) 2023-08-23
CL2019002850A1 (es) 2020-03-13
CN114984209A (zh) 2022-09-02
CL2021003196A1 (es) 2022-09-23
KR20190137105A (ko) 2019-12-10
TWI822101B (zh) 2023-11-11
AU2022204078A1 (en) 2022-06-30
KR20220083863A (ko) 2022-06-20
RU2019134934A (ru) 2021-05-05
RU2019134934A3 (ko) 2022-01-14
EP4116328A1 (en) 2023-01-11
MX2019011961A (es) 2019-12-05
CA3058960C (en) 2023-08-29
IL269644A (en) 2019-11-28
EA201992350A1 (ru) 2020-03-23
MA49042A (fr) 2020-02-12
US11939380B2 (en) 2024-03-26
AU2018247916A1 (en) 2019-10-17
BR112019020662A2 (pt) 2020-05-05
CO2019012080A2 (es) 2020-01-17
JP2024023222A (ja) 2024-02-21
US20220380470A1 (en) 2022-12-01
MX2022007140A (es) 2022-07-19
US20200407444A1 (en) 2020-12-31
TW202235106A (zh) 2022-09-16
TW201841652A (zh) 2018-12-01
WO2018185232A1 (en) 2018-10-11
CA3058960A1 (en) 2018-10-11
CA3185303A1 (en) 2018-10-11
JP2020513009A (ja) 2020-04-30
CN110621698B (zh) 2024-04-12
TWI801376B (zh) 2023-05-11
JP2022133296A (ja) 2022-09-13

Similar Documents

Publication Publication Date Title
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201809082WA (en) Nlrp3 modulators
SG11201811432WA (en) Rna for cancer therapy
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201811184UA (en) Lag -3 binding members
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201903737PA (en) Neutralizing anti-tl1a monoclonal antibodies
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201906557UA (en) Novel stable formulation for fxia antibodies
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201805771XA (en) Systems and methods for preparation of platelets